

# Relief from Common Digestive Distress

## References

1. Taylor J, Landry E, Lalonde L, Tsuyuki RT. Results of a national survey on over-the-counter medicines, Part 1: Pharmacist opinion on current scheduling status. *Can Pharm J (Ott)*. 2012; 145(1):40-4.
2. Sheen CL, Colin-Jones DG. Review article: over-the-counter drugs and the gastrointestinal tract. *Alimen Pharmacol Ther*. 2001;15(9):1263-70.
3. Van Vliet EP, Kuipers EJ, Steyerberg EW, Siersema PD. Users and utilization patterns of over-the-counter acid inhibitors and antacids in The Netherlands. *Scand J Gastroenterol*. 2008;43(6):662-8.
4. Available at: <http://goo.gl/kyZrkD>. Accessed August 6, 2013.
5. Farges MC, Vasson MP, Davot P, et al. Supplementation of oral nutrition with pancreatic enzymes improves the nutritional status of aged endotoxemic rats. *Nutrition*. 1996;12(3):189-94.
6. Available at: <http://goo.gl/JttyqX>. 2008. Accessed August 6, 2013.
7. Di Stefano M, Veneto G, Malservisi S, Strocchi A, Corazza GR. Lactose malabsorption and intolerance in the elderly. *Scand J Gastroenterol*. 2001;36(12):1274-8.
8. Baum BJ, Levine RL, Kuyatt BL, Sogin DB. Rat parotid gland amylase: evidence for alterations in an exocrine protein with increased age. *Mech Aging Dev*. 1982;19(1):27-35.
9. Laugier R, Bernard JP, Berthezene P, Dupuy P. Changes in pancreatic exocrine secretion with age: pancreatic exocrine secretion does decrease in the elderly. *Digestion*. 1991;50(3-4):202-11.
10. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. *World J Gastroenterol*. 2010;16(24):2978-90.
11. Kirsch M. Bacterial overgrowth. *Am J Gastroenterol*. 1990;85(3):231-7.
12. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. *JAMA*. 2004;292(7):852-8.
13. Vitetta L, Manuel R, Zhou JY, Linnane AW, Hall S, Coulson S. The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures. *Pharmaceuticals (Basel)*. 2014;7(9):954-89.
14. Vellas B, Balas D, Moreau J, et al. Exocrine pancreatic secretion in the elderly. *Int J Pancreatol*. 1988;3(6):497-502.
15. Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. *Clin Exp Gastroenterol*. 2011;4:55-73.
16. Friess H, Michalski CW. Diagnosing exocrine pancreatic insufficiency after surgery: when and which patients to treat. *HPB (Oxford)*. 2009;11 Suppl 3:7-10.
17. Dominguez-Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. *Gastroenterol Hepatol*. 2011;7(6):401-3.
18. Eun JS, Beauchemin KA. Effects of a proteolytic feed enzyme on intake, digestion, ruminal fermentation, and milk production. *J Dairy Sci*. 2005;88(6):2140-53.
19. Omogbenigun FO, Nyachoti CM, Slominski BA. Dietary supplementation with multienzyme preparations improves nutrient utilization and growth performance in weaned pigs. *J Anim Sci*. 2004;82(4):1053-61.
20. Knill-Jones RP, Pearce H, Batten J, Williams R. Comparative trial of Nutrizym in chronic pancreatic insufficiency. *BMJ*. 1970;4(5726):21-4.
21. Griffin SM, Alderson D, Farndon JR. Acid resistant lipase as replacement therapy in chronic pancreatic exocrine insufficiency: a study in dogs. *Gut*. 1989;30(7):1012-5.
22. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. *Dig Dis Sci*. 1999;44(7):1317-21.
23. Misselwitz B, Pohl D, Fruhauf H, Fried M, Vavricka SR, Fox M. Lactose malabsorption and intolerance: pathogenesis, diagnosis and treatment. *United European Gastroenterol J*. 2013;1(3):151-9.

24. Kuhn RJ, Gelrud A, Munck A, Caras S. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency. *Adv Ther*. 2010;27(12):895-916.
25. Park S, Johnson MA. What is an adequate dose of oral vitamin B12 in older people with poor vitamin B12 status? *Nutr Rev*. 2006;64(8):373-8.
26. Sanders SW, Tolman KG, Reitberg DP. Effect of a single dose of lactase on symptoms and expired hydrogen after lactose challenge in lactose-intolerant subjects. *Clin Pharm*. 1992;11(6):533-8.
27. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. *Nutrients*. 2012;4(8):1095-1119.
28. De Vos WM, de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. *Nutr Rev*. 2012;70 Suppl 1:S45-56.
29. Semova I, Carten JD, Stombaugh J, et al. Microbiota regulate intestinal absorption and metabolism of fatty acids in the zebrafish. *Cell Host Microbe*. 2012;12(3):277-88.
30. Rana SV, Malik A. Hydrogen breath tests in gastrointestinal diseases. *Indian J Clin Biochem*. 2014;29(4):398-405.
31. Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review. *Alt Med J*. 2004;9(2):180-97.
32. Goepp J, Fowler E, McBride T, Landis D. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. *Glob Adv Health Med*. 2014;3(3):9-15.
33. Zhang YJ, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on human health and diseases. *Int J Mol Sci*. 2015;16(4):7493-519.
34. Saffrey MJ. Aging of the mammalian gastrointestinal tract: a complex organ system. *Age*. 2014;36(3):9603.
35. Available at: <http://goo.gl/uAE8Lw>. Accessed August 6, 2013.
36. Majeed M, Prakash L. Majeed M, Prakash, L. Probiotics for health and wellbeing: Sabinsa Corporation;2007.
37. AMR. Lactobacillus sporogenes. *Alt Med Rev*. 2002;7(4):340-2.
38. Sabinsa. LactoSpore: Frequently Asked Questions. 2012.
39. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK44619/>. Accessed August 6, 2015.
40. Sivakumar A. A randomized, double blind, parallel group, placebo controlled study to evaluate the safety and efficacy of Lactospore(Bacillus coagulans MTCC 5856) in patients with diarrhea predominant irritable bowel syndrome: Sami Labs Limited; 2014. 2014.
41. Barrett JS. Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. *Nutr Clin Pract*. 2013;28(3):300-6.
42. Sjolund K, Haggmark A, Ihse I, Skude G, Karnstrom U, Wikander M. Selective deficiency of pancreatic amylase. *Gut*. 1991;32(5):546-8.
43. Gudmand-Hoyer E. The clinical significance of disaccharide maldigestion. *Am J Clin Nutr*. 1994;59(3 Suppl):735S-41S.
44. Available at: <http://goo.gl/XYnsXm>. ND. Accessed August 6, 2013.
45. Larque E, Sabater-Molina M, Zamora S. Biological significance of dietary polyamines. *Nutrition*. 2007;23(1):87-95.
46. Prester L. Biogenic amines in fish, fish products and shellfish: a review. *Food Addit Contam*. 2011;28(11):1547-60.
47. Macfarlane GT, Cummings JH, Allison C. Protein degradation by human intestinal bacteria. *J Gen Microbiol*. 1986;132(6):1647-56.
48. Kim E, Coelho D, Blachier F. Review of the association between meat consumption and risk of colorectal cancer. *Nutr Res*. 2013;33(12):983-94.
49. Iovanna J, Giorgi D, Dagorn JC. Newly synthesized amylase, lipase and serine proteases are transported at different rates in rat pancreas. *Digestion*. 1986;34(3):178-84.
50. Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. *WJG*. 2013;19(42):7258-66.
51. Pongprasobchai S. Maldigestion from pancreatic exocrine insufficiency. *J Gastroenterol Hepatol*. 2013;28 Suppl 4:99-102.
52. Carle-Urioste JC, Escobar-Vera J, El-Gogary S, et al. Cellulase induction in *Trichoderma reesei* by cellulose requires its own basal expression. *J Bio Chem*. 1997;272(15):10169-74.

53. Goncalves P, Martel F. Butyrate and colorectal cancer: the role of butyrate transport. *Curr Drug Metab.* 2013;14(9):994-1008.
54. Eswaran S, Muir J, Chey WD. Fiber and functional gastrointestinal disorders. *Am J Gastroenterol.* 2013;108(5):718-27.
55. Fraissl L, Leitner R, Missbichler A. Novel formulation of neutral lactase improves digestion of dairy products in case of lactose intolerance. *Clin Transl Allergy.* 2011;1(Suppl 1):P104.
56. Swagerty DL, Jr., Walling AD, Klein RM. Lactose intolerance. *Am Fam Physician* 2002;65(9):1845-50.
- 57.